Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI® Surgical System in Pseudophakic Glaucoma Patients with Uncontrolled Pressure Following a Previous Combination Cataract Stent Procedure
Multicenter Clinical Data from Five US sites Published in International Ophthalmology
Excerpt from the Press Release:
- Worldwide, more than one million trabecular microbypass stents have been implanted in combination with cataract surgery.
- Despite glaucoma medications and prior microbypass stenting, target IOP may no longer be achieved over time.
- During 3 to 42 months follow-up, the majority of these standalone study patients treated with OMNI regained IOP control and avoided traditional surgery.
Click the button below to read the entire Press Release:
MENLO PARK, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced International Ophthalmology has published clinical data demonstrating the safety and effectiveness of the OMNI Surgical System as a minimally invasive, implant-free standalone (not in combination with cataract surgery) glaucoma procedure for pseudophakic glaucoma patients with a history of trabecular microbypass stent implantation (iStent® or iStent Inject®) whose pressure is no longer controlled by the bypass stent and IOP-lowering medications.
“Glaucoma is a chronic disease, and most patients will need a variety of treatments over the course of their lives. Compliance with daily glaucoma medications can be low, and depending on the patient and stage of disease progression, some interventions such as bypass stents and/or IOP-lowering medications may run their natural course and no longer control the disease,” said Deepan Selvadurai, MD, a glaucoma specialist and cataract surgeon at Buffalo Ophthalmology in Buffalo, New York, and a clinical investigator and co-author of the study. “The OMNI Surgical System offers a potent implant-free procedure that I have found to be effective and durable in my pseudophakic patients where I had previously implanted trabecular bypass stents at the time of cataract surgery. This study showed that canaloplasty followed by trabeculotomy with OMNI as a standalone procedure in pseudophakic eyes with stents was highly effective in reducing IOP.”
The OMNI Surgical System is an implant-free procedure that uniquely addresses all three known points of resistance in the aqueous outflow system: the trabecular meshwork, Schlemm’s canal, and the collector channels.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?